Novel oral anticoagulants for the prevention and treatment of thromboembolism

Carrie S. Oliphant, Anna Jacobs, Rajesh Kabra, Pranab Das

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Over the last 5 years, new oral anticoagulant options, including dabigatran, rivaroxaban and apixaban, have become available. Prior to this, vitamin K antagonists were the sole oral anticoagulants, which have been in use for more than 60 years. These novel agents have been studied in a variety of patient populations, including atrial fibrillation, acute coronary syndrome, treatment of venous thromboembolism and thromboprophylaxis. Compared with standard care, these agents have largely been found to be noninferior or superior for efficacy end points, with similar or improved rates of bleeding. As a result, these agents have become attractive alternatives to vitamin K antagonists for the prevention and treatment of thromboembolic disease. This article provides a summary of clinical trial data to help clinicians determine which agent is most appropriate for a given patient.

Original languageEnglish (US)
Pages (from-to)849-861
Number of pages13
JournalFuture Cardiology
Volume9
Issue number6
DOIs
StatePublished - Nov 2013

Fingerprint

Vitamin K
Thromboembolism
Anticoagulants
Venous Thromboembolism
Acute Coronary Syndrome
Atrial Fibrillation
Clinical Trials
Hemorrhage
Therapeutics
Population
Rivaroxaban
Dabigatran
apixaban

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine
  • Molecular Medicine

Cite this

Novel oral anticoagulants for the prevention and treatment of thromboembolism. / Oliphant, Carrie S.; Jacobs, Anna; Kabra, Rajesh; Das, Pranab.

In: Future Cardiology, Vol. 9, No. 6, 11.2013, p. 849-861.

Research output: Contribution to journalReview article

Oliphant, Carrie S. ; Jacobs, Anna ; Kabra, Rajesh ; Das, Pranab. / Novel oral anticoagulants for the prevention and treatment of thromboembolism. In: Future Cardiology. 2013 ; Vol. 9, No. 6. pp. 849-861.
@article{514f99f1e62147eabb8db550c4f93e16,
title = "Novel oral anticoagulants for the prevention and treatment of thromboembolism",
abstract = "Over the last 5 years, new oral anticoagulant options, including dabigatran, rivaroxaban and apixaban, have become available. Prior to this, vitamin K antagonists were the sole oral anticoagulants, which have been in use for more than 60 years. These novel agents have been studied in a variety of patient populations, including atrial fibrillation, acute coronary syndrome, treatment of venous thromboembolism and thromboprophylaxis. Compared with standard care, these agents have largely been found to be noninferior or superior for efficacy end points, with similar or improved rates of bleeding. As a result, these agents have become attractive alternatives to vitamin K antagonists for the prevention and treatment of thromboembolic disease. This article provides a summary of clinical trial data to help clinicians determine which agent is most appropriate for a given patient.",
author = "Oliphant, {Carrie S.} and Anna Jacobs and Rajesh Kabra and Pranab Das",
year = "2013",
month = "11",
doi = "10.2217/fca.13.76",
language = "English (US)",
volume = "9",
pages = "849--861",
journal = "Future Cardiology",
issn = "1479-6678",
publisher = "Future Medicine Ltd.",
number = "6",

}

TY - JOUR

T1 - Novel oral anticoagulants for the prevention and treatment of thromboembolism

AU - Oliphant, Carrie S.

AU - Jacobs, Anna

AU - Kabra, Rajesh

AU - Das, Pranab

PY - 2013/11

Y1 - 2013/11

N2 - Over the last 5 years, new oral anticoagulant options, including dabigatran, rivaroxaban and apixaban, have become available. Prior to this, vitamin K antagonists were the sole oral anticoagulants, which have been in use for more than 60 years. These novel agents have been studied in a variety of patient populations, including atrial fibrillation, acute coronary syndrome, treatment of venous thromboembolism and thromboprophylaxis. Compared with standard care, these agents have largely been found to be noninferior or superior for efficacy end points, with similar or improved rates of bleeding. As a result, these agents have become attractive alternatives to vitamin K antagonists for the prevention and treatment of thromboembolic disease. This article provides a summary of clinical trial data to help clinicians determine which agent is most appropriate for a given patient.

AB - Over the last 5 years, new oral anticoagulant options, including dabigatran, rivaroxaban and apixaban, have become available. Prior to this, vitamin K antagonists were the sole oral anticoagulants, which have been in use for more than 60 years. These novel agents have been studied in a variety of patient populations, including atrial fibrillation, acute coronary syndrome, treatment of venous thromboembolism and thromboprophylaxis. Compared with standard care, these agents have largely been found to be noninferior or superior for efficacy end points, with similar or improved rates of bleeding. As a result, these agents have become attractive alternatives to vitamin K antagonists for the prevention and treatment of thromboembolic disease. This article provides a summary of clinical trial data to help clinicians determine which agent is most appropriate for a given patient.

UR - http://www.scopus.com/inward/record.url?scp=84887227261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887227261&partnerID=8YFLogxK

U2 - 10.2217/fca.13.76

DO - 10.2217/fca.13.76

M3 - Review article

VL - 9

SP - 849

EP - 861

JO - Future Cardiology

JF - Future Cardiology

SN - 1479-6678

IS - 6

ER -